Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
The review presents a discussion on articles and patents, describing new in vitro and in vivo models of pigmented or non-pigmented human cutaneous melanoma, received in NMRCO from the patients» metastases. Molecular genetic characteristics of the new models is supported by the arguments in addition to the given data and visual materials. The subjects of the discussed publications are 3 polyclonal cell lines, 2 subclones and 4 subcutaneous (s/c) xenografts in immunodeficient mice Balb/c nude. All the models are stored in Cryo Collection with xenografts at N.N. Blokhin NMRCO as well as in the Russian Collection of Cell Cultures of Vertebrae (RCCCV, St. Petersburg). This mini-collection is recommended for use in basic research of cutaneous melanoma and pre-clinical studies of anti-melanoma agents. The basis for these studies are the appropriate characteristics of the models, including cytological, immunologic, transplantation and molecular-genetic ones, as well as in vivo drug sensitivity to the corresponding target therapy.
Publisher
Publishing House ABV Press
Reference30 articles.
1. Demidov L.V., Utyashev I.A., Kharkevich G.Yu. Podkhody k diagnostike i terapii melanomy kozhi: era personalizirovannoi meditsiny. Dermatologiya. Consilium medicum (prilozhenie) 2013;2–3:42–7. [Demidov L.V., Utyashev I.A., Kharkevich G.Y. Approaches to the diagnosis and therapy of melanoma: the era of personalized medicine. Dermatology. Consilium medicum (Annex) 2013;2–3:42–7. (In Russ.)].
2. Inman S. GSK drug combination approved for advanced melanoma. Am J Manag Care 2014;20(2 Spec No.): E10. PMID: 25764581.
3. Jaiswal B.S., Janakiraman V., Kljavin N.M. et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 2009;4(5):e5717. PMID: 19492075. DOI: 10.1371/journal.pone.0005717.
4. Colombino M., Capone M., Lissia A. et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30(20):2522–9. PMID: 22614978. DOI: 10.1371/journal.pone.0005717.
5. Ascierto P.A., Schadendorf D., Berking C. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14(3):249–56. PMID 23414587. DOI: 10.1016/S1470-2045(13)70024-X.